NCT00305747View on ClinicalTrials.gov

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Prostate Cancer
Interventions
DRUG

BR-DIM

75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.

Trial Locations (2)

48334

Weisberg Cancer Treatment Center, Detroit

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00305747 - Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy | Biotech Hunter | Biotech Hunter